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CRT responseAbstract Cardiac resynchronization therapy (CRT) is established in the management patients with
moderate to severe symptoms due to left ventricular systolic dysfunction who present with signs of
electrical dyssynchrony. There is wide variability in the clinical response and improvement in LVEF
with CRT. Prediction of response to CRT is an important goal in order to tailor this therapy to
patients most apt to derive benefit. Aim: The aim of the study was to assess and identify the best
predictors of CRT response. Patients and methods: The study included 170 consecutive heart failure
(HF) patients in New York Heart Association (NYHA) functional class III or IV and LVEF
6 35%. Routine device and clinical follow-up, as well as CRT optimization, were performed at
baseline and at 3-month intervals. Responders were defined as having an absolute reduction in left
ventricular end-systolic diameter >15% and an improvement in LVEF >10%. Results: 170
patients were included [71.1% men; mean age 68.8 ± 9.7 years; 159 patients NYHA class III, 11
patients ambulatory NYHA class IV; 91 patients had non-ischemic cardiomyopathy (ICM) – 79
patients had ICM; 55.3% of patients had LBBB; mean QRS duration 145 ± 25 ms; left ventricular
ejection fraction 28.38 ± 7.2]. CRT-P was implanted in 65 patients and CRT-D was implanted in
105 patients. CRT response was achieved in 114 patients (67.1%). Mean LVEF improved
from 28.38 ± 7.2% to 35.46 ± 9.3% (p= 0.001), mean LV end-diastolic diameter reduced from
67.91 ± 8.7 to 64.95 ± 8.9 mm (p< 0.001), and mean LV end-systolic diameter reduced from
57.02 ± 8.8 to 52.42 ± 9.9 mm (p< 0.001). Responders had significantly wider baseline QRS
duration, lower BMI, lower baseline serum creatinine level, smaller baseline RV diastolic dimension
and significantly greater tricuspid annular peak systolic excursion (TAPSE) value. In multi-nominal
regression analysis to identify the pre-implantation predictors of response, QRS duration >150 ms,
non-ICM, TAPSE >15 mm, sinus rhythm, the absence of COPD and the absence of renal disease
were the independent predictors of CRT response. We generated a new CRT score to predict
responders to CRT. The score consists of maximum 9 points. The CRT response rate has been
markedly different according to the CRT score: CRT response rate was 97.5% patients with
CRT score >6 vs 40.7% if CRT score <6, p< 0.001. Conclusion: Only some of the commonly
228 M. Loutfi et al.used response criteria predict outcome in patients undergoing CRT. The newly generated CRT
score may be used to improve the appropriate use of CRT, to increase the CRT response rate. This
score needs to be validated on another population of patients.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Heart failure (HF) is a major public health problem, with a
prevalence of more than 23 million worldwide.1 Trials of car-
diac resynchronization therapy (CRT) have consistently shown
improvement of HF morbidity, quality of life, and survival in
patients with reduced left ventricular ejection fraction (LVEF),
advanced HF symptoms, and increased QRS duration.2,3
Guidelines recommend CRT implantation in symptomatic
HF patients with sinus rhythm, low LVEF, and a prolonged
QRS duration.4,5 Recent guidelines expanded the indications
for CRT to include less severe symptoms (NYHA class I and
II), and patients with non-LBBB only with a QRS
P150 ms.6–9
Despite the majority of patients derive benefit from CRT,
about two-third of the patients who meet the current guideli-
nes criteria for this therapy responds to the therapy. It is gen-
erally estimated that 30–35% of patients do not respond to
CRT.9–11 There is wide variability in the extent of LV remod-
eling and improvement in LVEF with CRT.12 Lack of
response to CRT may be attributed to current selection criteria
including only functional class, LVEF, QRS duration, and
QRS morphology.9 As a considerable proportion of eligible
patients still fail to benefit from this treatment, identification
of potential responders to CRT is an important goal to recom-
mend this therapy to patients most apt to derive benefit.132. Aim
The aim of the study was to assess and identify the best predic-
tors of CRT response and to generate a new simple score to
predict the response to CRT in order to improve patient selec-
tion for CRT implantation.3. Patients and methods
One hundred and seventy patients were included in this study.
All patients underwent successful implantation procedure at
Alexandria Main University Hospital, Egypt/Zentraklinik
Bad Berka, Germany, during 2010 and 2011. All patients pro-
vided oral and written informed consent to device implanta-
tion and agreed to data retrieval and analysis. All patients
met the criteria for CRT implantation, including moderate
and severe HF (NYHA II, III and ambulatory IV), persistent
symptoms despite optimal medical treatment, severely
depressed LVEF (635%) and QRS duration P120 ms (or
echocardiographic evidence of LV dyssynchrony if QRS dura-
tion <120 ms). Patients were classified as having HF of
ischemic or non-ischemic etiology based on a history ofmyocardial infarction or based on objective evidence of coro-
nary artery disease as assessed with coronary angiography.
Exclusion criteria:
 Patients with previously implanted pacemaker.
 Patients with previous PCI or CABG 66 m before
implantation.
 ACS 66 m before implantation.
 Failed CRT implantation or lead dislocation in the 1st
6 months after implantation requiring re-implantation.3.1. Procedure details
All leads were implanted transvenously, through the left-sided
or right-sided cephalic or subclavian veins, connected to a
biventricular pacemaker as described previously.14 The LV
lead position was targeted to the lateral coronary vein; if
unavailable, the posterolateral coronary vein, a posterior vein
or anterior vein was used. When a conventional indication
for an implantable cardioverter–defibrillator (ICD) existed, a
combined device (CRT-D) was implanted.
3.2. Follow-up
Routine device and clinical follow-up, as well as CRT opti-
mizations, were performed at baseline and at 3-month inter-
vals. Patients were assessed for response after 6 months as
follows:
 Responders (combined clinical and echocardiographic):
– Clinical response: Improvement in NYHA functional
class (at least one class) and increase of the 6 min walk
distance P10%.
– Echocardiographic response: absolute reduction in left
ventricular end-systolic diameter >15% and or impro-
vement in LVEF >10%.
 Non-responders: Unchanged or worsening of the clinical or
echocardiographic parameters, any hospitalization for
unprovoked worsening of heart failure or cardiac mortality
due to worsening heart failure during the first 6 months
after implantation.
3.3. Statistical analysis
Results for continuous variables are presented as mean & SD
and for discrete variables as frequency (%). A p value <0.05
was considered statistically significant and all tests were 2-
sided. Differences between baseline and follow-up characteris-
tics in the same patients were investigated by paired t tests for
continuous variables. Differences between groups were tested
Table 2 Baseline ECG and echocardiographic characteristics.
Mean/n (%)
Baseline ECG
QRS duration
Mean (ms) 145 ± 26
P150 (ms) 89 (52.3%)
QRS morphology
LBBB 94 (55.3%)
RBBB 4 (2.3%)
IVCD 47 (27.6)
Normal 25 (14.7%)
Rhythm
Sinus rhythm at CRT implantation 147 (86.5%)
AF at CRT implantationa 23 (13.5%)
Baseline echocardiography
LV dimensions, volumes and EF
LVIDd (mm) 67.58 ± 9.2
LVIDs (mm) 55.71 ± 10.3
LVEDV (ml) 205.72 ± 66.4
LVESV (ml) 148.30 ± 56
LVEF% 28.31 ± 7.2%
Right ventricle
TAPSE (mm) 17.9 ± 3.6
RVd (mm) 34.15 ± 5.9
PAP > 50 mmHg 43 (25.3%)
Markers of dyssynchrony
SPWMD (ms) 120.73 ± 63.3
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analysis of variance for comparison of continuous variables.
Univariate odds ratios (OR) and 95% confidence intervals
(CIs) were calculated and multivariate stepwise nominal logis-
tic regression analyses were used for identifying variables pre-
dictive of response to CRT. In the stepwise procedure all
variables significant at univariate analysis were entered. All
statistical analyses were performed using SPSS for Windows,
version 20 (SPSS Inc, Chicago, IL).
3.4. Ethics statement
This study was reviewed and approved by the Faculty of Med-
icine, University of Alexandria review board. All patients were
informed about the technique and we obtained an informed
consent.
4. Results
170 patients were included [77.1% men; mean age 68.8
± 9.7 years; 159 patients NYHA class III, 11 patients ambula-
toryNYHAclass IV; 91 patients hadnon-ischemic cardiomyopa-
thy (ICM) – 79 patients had ICM; 55.3% of patients had LBBB;
mean QRS duration 145 ± 25 ms; left ventricular ejection
fraction 28.38 ± 7.2]. CRT-P was implanted in 65 patients
and CRT-D was implanted in 105 patients. BaselineTable 1 Baseline characteristics; clinical data.
Baseline condition Mean/n (%)
Age (years) 68.8 ± 9.7
Male/female (n) 121/49
NYHA II (n) 23 (13.5%)
NYHA III (n) 136 (80%)
Ambulatory NYHA IV (n) 11 (6.5%)
6 min walk distance (m) 275 ± 105
NICM (n) 91 (53.5%)
ICM (n) 79 (46.5%)
Previous MI (n) 43 (25.3%)
Previous revascularization (n) 60 (35.3%)
BMI (kg/m2) 29.2 ± 5.1
Use of medications (% of patients)
B blockers 94%
ACEi/ARB 95%
MRA 64%
Diuretics 92%
Statins 69%
Digoxin 41%
Antiarrhythmic drugs 29%
Comorbidities
Hypertension (n) 139 (81.7%)
Diabetes mellitus (n) 86 (50.5%)
COPD (n) 44 (25.8%)
BMI > 30 (n) 55 (32.3%)
History of renal disease (n) 56 (32.9%)
S. Creatinine (mg/dl) 1.2 ± 0.4
Blood urea nitrogen (mg/dl) 9.5 ± 6.4
eGFR (ml/min/1.73 m2) 53.7 ± 10.3
MRA: mineralocorticoid receptor antagonist, COPD: chronic
obstructive pulmonary disease, BMI: body mass index, and eGFR:
estimated glomerular filtration rate.
LVFT/RR% 37.64 ± 8.3%
LVPEI (ms) 128.50 ± 30.4
IVD (ms) 39.28 ± 25.9
Ts-sep-lat (ms) 63.22 ± 34.7
LVPEI (ms) 128.50 ± 30.4
IVD (ms) 39.28 ± 25.9
Ts- sep-lat (ms) 63.22 ± 34.7
IVCD: Intraventricular conduction delay.
a AV nodal ablation was done in 8 patients. LVIDd: left ven-
tricular internal dimension at end diastole, LVIDS: left ventricular
internal dimension at end systole, LVEDV: left ventricular end
diastolic volume, LVESV: left ventricular end systolic volume,
LVEF: left ventricular ejection fraction, TAPSE: tricuspid annular
peak systolic excursion, RVd: right ventricular dimension, PAP:
pulmonary artery pressure, SPWMD: septal-posterior wall motion
delay, LV FT/RR: left ventricular filling time (LVFT) in relation to
cardiac cycle length (RR) as measured by transmitral Doppler
expressed as percentage, LVPEI: Left ventricular pre-ejection
interval, IVD: interventricular delay, and Ts-sep-lat: delay between
time to peak systolic velocity in ejection phase at basal septal and
basal lateral segments.characteristics; clinical data, baseline electocardiographic and
echocardiographic characteristics are shown in Tables (1–2).
CRT response was achieved in 114 patients (67.1%). Mean
LVEF improved from 28.38 ± 7.2% to 35.46 ± 9.3%
(p= 0.001), mean LVEDD reduced from 67.91 ± 8.7 to
64.95 ± 8.9 mm (p< 0.001), and mean LVESD reduced from
57.02 ± 8.8 to 52.42 ± 9.9 mm (p< 0.001). In univariate anal-
ysis (Table 3) responders had significantly wider baseline QRS
duration (QRS > 150 ms), LBBB pattern, sinus rhythm, female
gender, non-ICM, lower baseline serum creatinine level, the
absence of COPD, the absence of Grade III diastolic dysfunc-
tion, PAP < 50 mmHg, smaller baseline RV diastolic dimen-
sion and significantly greater tricuspid annular peak systolic
excursion (TAPSE) value. In multi-nominal regression analysis
Table 3 Univariate of CRT response with different parameters.
CRT response p
Non-responder (n= 52) Responder (n= 118)
Gender Female 5 (9.6%) 44 (37.3%) <0.001*
Male 47 (90.4%) 74 (62.7%)
HF etiology Ischemic 34 (65.4%) 45 (38.1%) 0.001*
Non-ischemic 18 (34.6%) 73 (61.9%)
Renal disease Present 25 (48.1%) 31 (26.3%) 0.005*
Absent 27 (51.9%) 87 (73.7%)
Lung disease Present 22 (42.3%) 22 (18.6%) 0.001*
Absent 30 (57.7%) 96 (81.4%)
Anemia <11 g/dl 50 (96.2%) 111 (94.1%) 0.724
>11 g/dl 2 (3.8%) 7 (5.9%)
Obesity <30 kg/m2 30 (57.7%) 71 (60.2%) 0.374
>30 kg/m2 19 (36.5%) 45 (38.1%)
Electrocardiographic parameters
Rhythm AF 12 (23.1%) 11 (9.3%) 0.016*
Sinus 40 (76.9%) 107 (90.7%)
QRS Morphology LBBB 16 (30.8%) 78 (66.1%) <0.001*
Non-LBBB 36 (69.2%) 40 (33.9%)
QRS duration <150 ms 38 (73.1%) 43 (36.4%) <0.001*
>150 ms 14 (26.9%) 75 (63.6%)
Echocardiographic baseline parameters
LVEF >25% 33 (63.5%) 69 (58.5%) 0.541
<25% 19 (36.5%) 49 (41.5%)
Diastolic dysfunction grade III Absent 35 (67.3%) 98 (83.1%) 0.022*
Present 17 (32.7%) 20 (16.9%)
TAPSE <15 cm/s 30 (57.7%) 31 (26.3%) <0.001*
>15 cm/s 22 (42.3%) 87 (73.7%)
RV dimension <35 mm 24 (46.2%) 76 (64.4%) 0.026*
>35 mm 28 (53.8%) 42 (35.6%)
Pulmonary artery pressure <50 mmHg 39 (75.0%) 96 (81.4%) 0.345
>50 mmHg 13 (25.0%) 22 (18.6%)
SPWD <130 ms 30 (44.8%) 37 (55.2%) 0.02
>130 ms 11 (21.2%) 41 (78.8%)
LV FT/RR <40% 21 (29.6%) 50 (70.4%) 0.188
>40% 16 (42.1%) 22 (57.9%)
LVPEI <140 ms 27 (36.5%) 47 (63.5%) 0.547
>140 ms 13 (31.0%) 29 (69.0%)
IVD <40 ms 21 (36.8%) 36 (63.2%) 0.315
>40 ms 15 (25.4%) 44 (74.6%)
Ts-sep-lat <60 ms 16 (35.6%) 29 (64.4%) 0.694
>60 ms 16 (28.6%) 40 (71.4%)
SPWMD <130 ms 30 (44.8%) 37 (55.2%) 0.02
>130 ms 11 (21.2%) 41 (78.8%)
MRPmoderate Absent 49 (94.2%) 109 (92.4%) 0.758
Present 3 (5.8%) 9 (7.6%)
230 M. Loutfi et al.(Table 4) to identify the pre-implantation predictors of response,
LBBB and QRS > 150 ms, sinus rhythm, female gender, non-ICM, the absence of COPD, the absence of renal disease, TAP-
SE > 15 mm, were the independent predictors of CRT.
Table 3 (continued)
CRT response p
Non-responder (n= 52) Responder (n= 118)
TRPmoderate Absent 32 (61.5%) 77 (65.3%) 0.642
Present 20 (38.5%) 41 (34.7%)
Optimal LV lead position Non-optimal 11 (21.2%) 6 (5.1%) 0.001*
Optimal 41 (78.8%) 112 (94.9%)
Qualitative data were expressed using number and percent and were compared using Chi square or Fisher exact test.
TAPSE: tricuspid annular peak systolic excursion, RV: right ventricle, SPWMD: septal-posterior wall motion delay, LV FT/RR: left ventricular
filling time (LVFT) in relation to cardiac cycle length (RR), LVPEI: left ventricular pre-ejection interval, IVD: interventricular delay, Ts-sep-lat:
delay between time to peak systolic velocity in ejection phase at basal septal and basal lateral segments, SPWMD: septal-posterior wall motion
delay, MR: mitral regurgitation, and TR: tricuspid regurgitation.
Table 4 Univariate and multivariate factors predicting response to CRT.
Univariate models Multivariate models
Total (n= 170) CRT response (n= 118) OR (95% CI) p OR (95% CI) p
Gender (female) 49 (28.8%) 44 (37.3%) 5.59* (2.06–15.1) 0.001* 5.56 (1.63–19.02) 0.006*
HF etiology (non-ischemic) 91 (53.5%) 73 (61.9%) 3.06* (1.55–6.05) 0.001* 2.57 (1.05–6.27) 0.038*
Absent renal disease 114 (67.1%) 87 (73.7%) 2.59* (1.31–5.13) 0.006* 1.73 (0.71–4.23) 0.028*
Absent lung disease 126 (74.1%) 96 (81.4%) 3.20* (1.55–6.59) 0.002* 3.30 (1.23–8.6) 0.015*
Anemia 161 (94.7%) 111 (94.1%) 0.634 (0.12–3.16) 0.576
Obesity 64 (37.6%) 45 (38.1%) 1.001 (0.50–1.98) 0.998
Electrocardiographic parameters
Sinus rhythm 147 (86.5%) 107 (90.7%) 2.92* (1.19–7.14) 0.019* 1.95 (0.59–6.38) 0.026*
LBBB morphology 94 (55.3%) 78 (66.1%) 4.38* (2.17-8.84) <0.001* 1.61 (0.64-4.09) 0.031*
QRS > 150 ms 89 (52.4%) 75 (63.6%) 4.73* (2.30–9.71) <0.001* 4.10 (1.65–10.2) 0.002*
Echocardiographic parameters
TAPSE> 15 cm/s 109 (64.1%) 87 (73.7%) 3.83* (1.92–7.60) <0.001* 5.16 (2.1–12.63) <0.001*
LVEF 68 (40.0%) 49 (41.5%) 1.233 (0.62–2.41) 0.541
Diastolic dysfunction G III 37 (21.8%) 20 (16.9%) 0.420 (0.19–0.89) 0.022* 1.134 (0.39–3.27) 0.817
RV dimension 70 (41.2%) 42 (35.6%) 0.474 (0.24–0.91) 0.026* 1.183 (0.42–3.32) 0.750
PAP> 50 mmHg 35 (20.6%) 22 (18.6%) 0.688 (0.31–1.50) 0.345
MRPmoderate 12 (7.1%) 9 (7.6%) 1.349 (0.35–5.19) 0.663
TRPmoderate 61 (35.9%) 41 (34.7%) 0.852 (0.43–1.67) 0.642
Optimal LV lead site 153 (90.0%) 112 (94.9%) 5.008 (1.74–14.41) 0.001* 6.985 (1.51–32.26) 0.013*
Qualitative data were described using number and percent and were compared using Chi square test, while normally quantitative data were
expressed in mean ± SD and were compared using student t-test.
* Statistically significant at p 6 0.05.
Figure 1 CRT response according to the CRT score.
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232 M. Loutfi et al.4.1. New score to predict CRT response
We generated a new CRT score to predict responders to CRT.
The score consists of maximum 9 points. All significant inde-
pendent pre-implantation predictors of CRT response in
multinominal logistic regression analysis were included in the
CRT score according to their relative effect in the regression
model to generate the CRT score. The CRT score includes
QRS duration P150 ms, LBBB morphology of.
The QRS complex, and non-ICM, sinus rhythm at time of
CRT implantation, preserved RV function with TAP-
SEP 15 mm, female gender, the absence of history of renal dis-
ease and finally the absence of significant COPD (based on
specialized respiratory assessment and use of specific medica-
tions). Each parameter was assigned to a single point except
QRSdurationP150 mswas assigned to2points.TheCRTscore
is the sum of all points. The CRT response rate has been mark-
edly different according to the CRT score, and CRT response
rate was 97.5% patients with CRT score >6 vs 40.7% if CRT
score<6, p< 0.001.CRT scorewas in conjunctionwith current
evidence about greater in patients with wider QRS complex,
LBBB, female gender and non-ICM6 (see Fig. 1, Table 5).
4.2. The CRT score in the scope of guidelines
According to the 2013 European Society of Cardiology guide-
lines on cardiac pacing and CRT, 85 of our patients met class IFigure 2 Study population classified according to ESC guidelines
Table 5 Points in the CRT score.
Parameter Points
QRSP 150 ms 2
LBBB 1
NICM 1
Sinus rhythm 1
Female gender 1
TAPSEP 15 mm 1
Absent renal disease 1
Absent lung disease 1
Total 9indication for CRT implantation, 34 met class IIa indication,
26 patients met class IIb and 25 met class III indication for
CRT implantation6 (see Fig. 2).
– Patients with class I indication for CRT implantation had a
response rate of 88.2%. The CRT score was P6 in 66
patients (65 (98.5%) responders), while the CRT score
was less than 6 in 18 patients (9 (50%) responders and,
p< 0.0001).
– Patients with class IIa indication for CRT implantation had
a response rate of 47.1%. The CRT score was >6 in 11
patients (11 (100%) responders), while the CRT score was
less than 6 in 23 patients (5 (21.7%) responders), p= 0.007.
– Patients who met class IIb/III indication for CRT implanta-
tion had a response rate of 45.1%. The CRT score was >6
in 5 patients (all are responders), while the CRT score was
less than 6 in 46 patients (18 (39.1%) responders),
p= 0.014.
5. Discussion
Cardiac resynchronization therapy is an established treatment
for HF patients with LV systolic dysfunction and wide QRS
complex. However, approximately 30% of patients receiving
CRT according to guidelines fail to benefit from this
treatment. Lack of response to CRT may be attributed to
inappropriate patient selection, currently based only on func-
tional class, LVEF, QRS duration and QRS morphology.9–11
Accumulating data support that targeted patient selection,
proper left ventricular lead implantation and optimal device
programming may enhance patient response to CRT.15 In
the present study, 114 patients (67.1%) responded to CRT
implantation. At 6-month follow-up, there was improvement
of P1 NYHA and 6 min walk distance. CRT implantation
was associated with significant improvement in LV dimen-
sions, LVEF, reduction of LVESV >15%, LV diastolic dys-
function and the grade of mitral regurgitation. There were
no significant effects on renal function and RV diastolic
dimension and function. This beneficial effect of CRT wasclass for indication of CRT implantation and CRT response.
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ical LBBB QRS morphology, non-ischemic cardiomyopathy
and NYHA class II/III patients.
Trials of CRT have consistently shown improvement in
symptoms, quality of life, LVEF and survival in selected
patients with HF. QRS duration is the main pre-
implantation factor which has been shown to have a major
impact on the efficacy of CRT.15 In the present study, respon-
ders had significantly prolonged baseline QRS duration than
non-responders (152 ± 24.9 ms vs. 130.7 ± 24 ms respec-
tively, P< 0.0001). The results are consistent with previous
data which showed significant CRT benefit in HF patients with
QRSP 150 ms.11,16 Cleland et al. conducted an individual
patient meta-analysis of five randomized trials assessing the
effects of CRT on morbidity and mortality in patients with
symptomatic HF. Multivariate model includes the following
baseline variables: age, sex, NYHA class, etiology, QRS mor-
phology, QRS duration, LVEF% and systolic blood pressure,
showed that only QRS duration predicted the magnitude of
the effect of CRT on outcomes, with an increasing benefit with
prolonged QRS duration (P140 ms).17
The COMPANION trial enrolled 1634 NYHA class III/IV
HF patients with a QRS interval of >120 ms, PR interval
>150 ms, and a left ventricular ejection fraction 635% who
were treated with optimal pharmacologic therapy. The trial
found that benefits in terms of reduction in mortality or hospi-
talization were maximal in patients with QRS duration
>168 ms.3 The CARE-HF study evaluated the effect of
CRT on morbidity and mortality in 813 patients with NYHA
class III or IV heart failure, and noted similar benefit of CRT
in patients with QRS duration >150 ms.2 The RAFT trial ran-
domized 1798 patients with NYHA class II–III HF, LVEF
630%, and QRS duration P120 ms to receive either an ICD
alone or an ICD plus CRT. The study recorded that the addi-
tion of CRT to an ICD produced a 7% reduction in the pri-
mary outcome of death from any cause or hospitalization for
HF.18 In contrast, Beshai et al. reported that CRT has not
been shown to provide any benefit in patients with narrow
QRS complex (<120 ms) and echocardiographic evidence of
LV mechanical dyssynchrony.19 Also, the EchoCRT study
showed that the use of CRT in NYHA class III–IV H patients
(LVEF 635%) with QRS duration <130 ms was associated
with no benefits and possible harm with significant increase
in the rate of death from cardiovascular causes.20
The presence of LBBB-type morphology is related to
greater likelihood of improvement after CRT.18,21 The
MADIT–CRT trial enrolled 1820 patients in NYHA class I
or II (85%) and with QRS P130 ms and LVEF 630%.
Patients were randomized 3:2 to CRT with ICD or ICD alone
and followed up for a mean of 2.4 years. The end point of the
study was the reduction in all-cause mortality and/or hospital-
izations for HF. The results showed that the primary clinical
end point was reduced only in patients with LBBB receiving
CRT, whereas the treatment in patients with RBBB or non-
specific intra-ventricular conduction delay increased the risk
of death compared with ICD only, regardless of QRS dura-
tion.22 The CARE-HF study evaluated the effect of CRT on
morbidity and mortality in 813 Patients with NYHA class
III or IV heart failure. After a mean follow-up of 29.4 months,
CRT reduced the primary end point (all-cause death or hospi-
talization for MACE) by 37% compared with medical therapy,
and only 35% of patients with RBBB morphology receivedsome benefit from CRT.23 Sipahi et al. conducted a recent
meta-analysis of 4 large randomized trials, totaling 5356
patients, confirmed the effect of CRT in reducing adverse clin-
ical events only inpatients with LBBB.21 Consistently, in the
present study there were less responders to CRT in patients
without LBBB.
In the present study, responders had significantly wider
baseline QRS duration than non-responders (152 ± 24.9 ms
vs. 130.7 ± 24 ms respectively, P< 0.0001). QRS duration is
the main pre-implantation factor which has been shown to
have a major impact on the efficacy of CRT. The results are
consistent with previous several meta-analyses which showed
significant CRT benefit in HF patients with QRS
P150 ms.11,16 Cleland et al. conducted an individual patient
meta-analysis of five randomized trials comparing CRT either
with no active device or with a defibrillator including the fol-
lowing baseline variables: age, sex, NYHA class, etiology,
QRS morphology, QRS duration, LVEF% and systolic blood
pressure. Multivariate model showed that only QRS duration
predicted the magnitude of the effect of CRT on outcomes,
with an increasing benefit with prolonged QRS duration.
The authors reported that QRS duration P140 ms confers a
high certainty of favorable response.17 Beshai et al. reported
that CRT has not been shown to provide any benefit in
patients with narrow QRS complex (<120 ms) and echocar-
diographic evidence of LV mechanical dyssynchrony.19 Fur-
thermore, in the EchoCRT study, the use of CRT in NYHA
class III–IV heart failure patients (LVEF 635%) with QRS
duration less than 130 ms was also associated with an excess
mortality due to a significant increase in the rate of death from
cardiovascular causes.24 Therefore, based on the existing state
of evidence patients with QRS duration <130 ms should not
be considered for CRT implantation.
In addition to QRS duration and morphology, several vari-
ables have been related to a favorable response to CRT. In the
present study, responders were more frequently females, have
sinus rhythm, non-ischemic etiology, lower BMI, lower base-
line serum creatinine level, smaller baseline RV diastolic
dimension, and greater TAPSE value and were less likely to
have PAP >50 mmhg at baseline than non-responders. There
were no significant differences between responders and non-
responders in echocardiographic measures of LV, echocardio-
graphic markers of dyssynchrony nor baseline NYHA class.
Similarly, secondary analyses from randomized trials have
shown that the presence of non-ischemic cardiomyopathy,25
and female gender,26,27 is predictors of significant clinical ben-
efit from CRT. Comorbidities such as severe RV dysfunction,
pulmonary hypertension, impaired renal function, and valvu-
lar disease also appear to diminish response.28–30 In a sub-
analysis of MADIT–CRT, Hsu et al. investigated predictors
of LVEF super-response to CRT-D in 191 patients. Six base-
line factors predicted LVEF super-response: female gender,
no prior myocardial infarction, QRS duration P150 ms,
LBBB on baseline ECG, body mass index <30 kg/m2, and
smaller baseline left atrial volume index.31
The usual target for CRT lead placement is the lateral or
posterolateral left ventricle.32 In the present study, optimal
short axis and long axis position of the LV lead was associated
with improved response to CRT. Patients with LV leads in a
lateral, posterior or posterolateral position compared to ante-
rior and anterolateral sites were more likely to be responders
(74.9% vs 53.3%, P= 0.005), and also they had better LVEF
234 M. Loutfi et al.after 6 months (37.4 + 10.5 vs. 28.9 + 11.9, P= 0.002).
Patients with LV leads in the apical position compared to basal
and mid cavity sites had significantly higher heart failure
related to mortality rates at 1 year (44.4% vs. 3.7%,
P< 0.001, hazard ratio = 2.41; 95% confidence interval,
1.62–2.81; P= 0.001) and lower LVEF after 6 months (27.1
+ 7.8 vs. 36.8 + 11, P= 0.007). Optimal LV lead position
(combined optimal long axis and short axis position) was an
independent predictor of CRT response (OR 11.3; 95% CI
2–63.8). The CRT response rate when optimal LV lead site
achieved was 71.2% vs. 29.4% with non-optimal LV lead site,
P< 0.0001.
Previous studies have suggested that LV lead placement in a
posterolateral or lateral coronary sinus branch is associated
with significantly increased CRT benefit as compared to ante-
rior lead location.33,34 In secondary analyses of the COMPA-
NION and MADIT–CRT trials, LV lead location along the
short axis (anterior vs lateral vs posterior wall) had no signif-
icant effect on the rate of heart failure hospitalization or mor-
tality.35,36 However, in practice, positioning the LV lead
transvenously is limited by the accessibility of suitable epicar-
dial coronary veins and of an individualized approach in selec-
tion of the optimal pacing site by targeting the most delayed
segment, and avoiding areas of myocardial scar is recom-
mended.37,38 Device optimization using device based auto-
mated algorithms was performed at the same implantation
day in 57.6% of our patients. There was no significant differ-
ence in CRT response rate between patients underwent device
optimization and others who didn’t undergo device optimiza-
tion (69.4% vs. 63.9% respectively, P= 0.09). The SMART-
AV trial, a multicentre double-blind study in 980 patients ran-
domized to either empirical AV delay of 120 ms, to AV delay
optimized according to the mitral inflow pattern (iterative
method) or to the Smart Delay algorithm. The results showed
that neither echocardiographically optimized AV delay, nor
AV delay optimized by the algorithm SmartDelay provided
incremental benefit in CRT patients.39
We developed a new simple CRT score based on pre-
implantation date to predict CRT response. The CRT score
consists of maximum 9 point. Initially all significant indepen-
dent pre-implantation predictors of CRT response in multi-
nominal logistic regression analysis were included in the
CRT score according to their relative effect in the regression
model to generate an initial CRT score. When LBBB and
female gender were added to other variables, the statistical
power of the score much increased, so they were included in
the final CRT score. The CRT score includes QRS duration
P150 ms, LBBB morphology of the QRS complex, non-
ischemic etiology of cardiomyopathy, sinus rhythm at time
of implantation, preserved RV function with TAPSE
>15 mm, female gender, the absence of history of renal
disease and finally the absence of significant COPD
(based on specialized respiratory assessment and use of
specific medications). Each parameter was assigned to a
single point except QRS duration >150 ms was assigned to
2 points. The CRT score is the sum of all points. The
CRT response rate has been markedly different according to
the CRT score. Patients with CRT score >6 had CRT
response rate of 97.5% vs only 40.7% if CRT score <6,
P< 0.001.
In a previous scoring model, factors that are associated
with favorable reserve remodeling were used to predict CRTresponders in the MADIT-CRT trial.22 Using regression anal-
ysis in the CRT with ICD (CRT-D) arm of the trial, 7 factors
associated with a favorable echocardiographic response
(defined as a 10% reduction in left ventricular end-diastolic
volume at 1 year) to CRT-D therapy were first identified:
female sex, non-ischemic cardiomyopathy, QRS duration
>150 ms, the presence of left bundle branch block on baseline
ECG, hospitalization for HF at any time before enrollment,
baseline left ventricular end-diastolic volume >125 ml/m2,
and baseline left atrial volume >40 ml/m2. Each of the 7 fac-
tors was assigned a numerical score on the basis of its relative
effect in the regression model. The factor with the lowest effect,
prior HF hospitalization, was assigned the lowest score of 1;
the intermediate factors, which included female sex, non-
ischemic cardiomyopathy, left bundle branch block, QRS
interval >150 ms, and left ventricular end diastolic volume,
were assigned a score of 2; the highest factor, left atrial vol-
ume, was assigned a score of 3. A response score was con-
structed by adding the number values of the factors
identified in each patient. Four patient groups were created
on the basis of the response scores. Group 1, the lowest score
quartile, had a score of 0–4, Group 2 had a score of 5–6,
Group 3 had a score of 7–8, and Group 4, the highest quartile,
had a score of 9–14. Cox proportional hazards regression mod-
eling showed that when compared to the ICD-only arm, CRT-
D patients in Group 2 and higher showed a significant reduc-
tion in the risk of HF or death, whereas Group 1 patients
derived no benefit. The degree of reduction was incremental
between groups with a 33% (p= 0.04), 36% (p= 0.03), and
69% (p= 0.001) risk reduction for Groups 2, 3, and 4, respec-
tively. Kang et al. established a 4-point score system derived
from clinical, echocardiographic and electrocardiographic
indexes including tricuspid annular plane systolic excursion
(TAPSE), longitudinal strain (LS), and complete LBBB com-
bined with a wide QRS duration. The authors concluded that
a CRT score >2 can help to predict positive response to CRT
effectively and reliably.40 Shen et al. generated a 7-point
patient selection score (PSS) based on six variables aiming to
improve patient selection for CRT. Patients with a PSS >4
are the most likely to respond to CRT. Using this score system,
a PSS score >4 can predict the probability of a CRT response
up to 88% in patients with heart failure and a wide QRS dura-
tion.41 Brunet-Bernard et al. evaluated a scoring system inte-
grating clinical, electrocardiographic, and echocardiographic
measurements to predict left ventricular reverse remodeling
after CRT. A new 7-point CRT response score termed L2-
ANDS2 includes Left bundle branch block (2 points), Age
>70 years, non-end-diastolic diameter <40 mm/m2, and sep-
tal flash (2 points). A score >5 had a high positive likelihood
ratio (+LR= 5.64), whereas a score <2 had a high negative
likelihood ratio (LR= 0.19).42 The newly generated CRT
score in the present study may be used to improve patient
selection for CRT implantation.6. Study limitations
The study sample was relatively small and the short duration
of follow-up in this study should be considered a limitation
of the present analysis. Therefore, our results did not provide
data on the predictive characteristics of various criteria in the
longer perspective. Our trial was not designed to assess
Cardiac resynchronization therapy in chronic heart failure patients 235different response criteria, and is based on a group of patients
included in two centers. Therefore, the studied population may
differ from the population treated with CRT in everyday prac-
tice. However, the advantage of such studies is the generation
of a new CRT score which may help to identify patients who
derive clinical benefit from CRT. Taking into account
aforementioned limitations, our study does not provide a
definitive solution of the problem, but should be considered as
hypothesis generating and indicating the need for further research.
7. Conclusion
CRT is an effective treatment for selected patients with chronic
HF and a prolonged QRS interval. Only some of the com-
monly used response criteria predict outcome in patients
undergoing CRT. The newly generated CRT score may be
used to improve the appropriate use of CRT, to increase the
CRT response rate. This score needs to be validated on
another population of patients in conjunction with ongoing
and future research which investigate ways to reduce the fre-
quency of non-response to CRT and to improve selection of
patients for treatment with CRT for the prevention of HF or
death.Disclosure
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